Results 71 to 80 of about 1,991 (194)

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy

Open Heart
Background Mavacamten has revolutionised the treatment of hypertrophic obstructive cardiomyopathy (HOCM) but requires frequent follow-up. Routine ECG may offer an accessible tool to indicate response to therapy.
Tienush Rassaf, Florian Buehning, Tobias Lerchner, Julia Vogel, Lea Kolk, Lukas Vogel, Katharina Seuthe, Peter Ferdinandy, Amir Abbas Mahabadi, Lars Michel   +9 more
doaj   +1 more source

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk

JACC: Case Reports
Background: Treatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging.
Omar M. Abdelfattah, MD, Robyn Bryde, MD, Kutaiba Nazif, MD, Matthew W. Martinez, MD   +3 more
doaj   +1 more source

Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy [PDF]

Hypertrophic obstructive cardiomyopathy (HCM) is the most common heterogeneous genetic cardiovascular disorder. Its pathophysiology involves left ventricular hypertrophy, increased fibrosis, hypercontractility, and reduced compliance.
Bansal, Alka, Gupta, Dharmendra, Jakhar, Punam, Kumar, Susheel, Makhija, Mahima, Sharma, Lokendra   +5 more
core   +2 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +1 more source

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +1 more source

Model‐Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract ...
Xiaojie Wu, Shilpa Puli, Nanye Chen, Zhuang Tian, Peiwen Hsu, Jing Sun, Cheng Lyu, Samira Merali, Jing Zhang   +8 more
doaj   +1 more source

Diagnosis and Treatment of Obstructive Hypertrophic Cardiomyopathy [PDF]

, 2023
Left ventricular outflow obstruction (LVOTO) and diastolic dysfunction are the main pathophysiological characteristics of hypertrophic cardiomyopathy (HCM)LVOTO, may be identified in more than half of HCM patients and represents an important determinant ...
Errico Federico Perillo, Felice Borrelli, Gaetano Todde, Giovanni Esposito, Grazia Canciello, Maria Angela Losi Maria Angela Losi, Raffaella Lombardi   +6 more
core  

Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.

PLoS ONE
BackgroundHypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT).
Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi   +8 more
doaj   +1 more source

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +1 more source